Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE)
A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial
Sponsor: DalCor Pharmaceuticals
Listed as NCT02525939, this PHASE3 trial focuses on Acute Coronary Syndrome and remains completed. Sponsored by DalCor Pharmaceuticals, it has been updated 16 times since 2016, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Mar 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Jul 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- DalCor Pharmaceuticals
- Medpace, Inc.
- Roche Molecular Systems, Inc
- The Montreal Health Innovations Coordinating Center (MHICC)
For direct contact, visit the study record on ClinicalTrials.gov .